Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.
What: Novartis is obtaining an exclusive worldwide development and commercialization license for Arvinas’s ARV-766 and entering an asset
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.
Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.
The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.
Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.
Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.
The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
